Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Enanta Pharmaceutica (NQ: ENTA ) 10.05 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Enanta Pharmaceutica < Previous 1 2 3 4 5 6 7 Next > Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET May 08, 2023 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19 May 08, 2023 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharma Earnings Preview May 05, 2023 Via Benzinga Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2023 May 02, 2023 From Enanta Pharmaceuticals, Inc. Via Business Wire Expert Ratings for Enanta Pharma March 22, 2023 Via Benzinga Enanta Pharmaceuticals's Earnings: A Preview February 06, 2023 Via Benzinga Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 Million April 25, 2023 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals Presents Data for its COVID-19 and Respiratory Syncytial Virus Programs at the 33rd European Congress of Clinical Microbiology and Infectious Diseases April 17, 2023 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus April 06, 2023 From Enanta Pharmaceuticals, Inc. Via Business Wire Earnings Outlook For Enanta Pharmaceuticals November 18, 2022 Via Benzinga Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) April 05, 2023 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research March 14, 2023 From Enanta Pharmaceuticals, Inc. Via Business Wire 10 Companies That Had Tons of Money in SVB When It Collapsed March 13, 2023 Silicon Valley Bank is gone but its clients are still here. Many prominent companies, and not just startups, had money in SVB. Via InvestorPlace Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research March 08, 2023 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference March 07, 2023 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET February 07, 2023 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference February 07, 2023 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022 January 31, 2023 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference January 06, 2023 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference January 03, 2023 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals to Participate in Two Investor Conferences in November November 22, 2022 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET November 21, 2022 From Enanta Pharmaceuticals, Inc. Via Business Wire Earnings Scheduled For November 21, 2022 November 21, 2022 Companies Reporting Before The Bell • Zepp Health (NYSE:ZEPP) is expected to report quarterly earnings at $0.54 per share on revenue of $186.58 million. Via Benzinga Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Fourth Quarter and Full Year Ended September 30, 2022 November 14, 2022 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 November 09, 2022 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals Presents New Preclinical Data for EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 at IDWeek™ 2022 October 19, 2022 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus October 17, 2022 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus October 03, 2022 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV Symposium September 29, 2022 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposium September 22, 2022 From Enanta Pharmaceuticals, Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.